Myosin Inhibitors The Next Generation

Article Cardiac & Cardiovascular Systems

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

Martin S. Maron et al.

Summary: This study evaluated the safety and efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). The results showed that aficamten significantly reduced left ventricular outflow tract gradients and improved clinical symptoms.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy

Milind Y. Desai et al.

Summary: This study found that mavacamten, an oral myosin inhibitor, significantly reduced the proportion of patients meeting guideline criteria for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy after 16 weeks.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis

Sara Saberi et al.

CIRCULATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy

Anne M. Dybro et al.

Summary: The study showed that metoprolol reduced LVOT obstruction, provided symptom relief, and improved quality of life in patients with obstructive HCM compared to placebo. However, maximum exercise capacity remained unchanged in both groups.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy

Sheila M. Hegde et al.

Summary: The BACKGROUND EXPLORER-HCM study showed that mavacamten can significantly improve left ventricular diastolic function and systolic anterior motion in patients with obstructive hypertrophic cardiomyopathy. Improvement in LVOT obstruction, LAVI, and E/e' was associated with reduction in a biomarker of myocardial wall stress.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy

Milind Y. Desai et al.

Summary: In patients with intractable symptoms of oHCM, mavacamten significantly reduced the proportion of patients meeting guideline criteria for SRT after 16 weeks.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems